Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00552825 |
Recruitment Status :
Completed
First Posted : November 2, 2007
Last Update Posted : November 2, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Acute Lymphoblastic Leukemia Acute Myeloblastic Leukemia Solid Tumors, Hodgkin's Disease Non-Malignant |
Pulmonary function tests (PFTs) are a part of the routine follow-up of patients receiving anti-cancer treatment. Treatment is frequently associated with diverse pulmonary damage which may become functionally and clinically evident many years later. PFTs may help to quantify the damage in the lungs; help to evaluate the point at which lung function deviates from normal to allow early intervention before irreversible lung damage occurs and thereby to reduce morbidity and mortality.
Reliable PFTs in the preschool age have traditionally been difficult to perform, but recent publications have demonstrated that the majority of preschool children can produce reproducible forced expiratory flow volume (FEVC) curves with proper coaching techniques. This recent development may enable studying the long term effect (years) of treatment on lung function in young children suffering from hemato-oncologic diseases.
Study Type : | Observational |
Actual Enrollment : | 35 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years |
Study Start Date : | October 2005 |
Actual Study Completion Date : | October 2006 |

Group/Cohort |
---|
1
all were in a single group
|

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years to 7 Years (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- All pediatric patients (age 3-7 years) with hemato-onclogic diseases that were treated at the Hemato-Oncology Department, and were sent to the pediatric pulmonary unit.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00552825
Israel | |
Sheba Medical CenterPediatric pulmonary unit, Pulmonary function laboratory | |
Ramat-Gan, Ramat Gan, Israel, 52621 |
Principal Investigator: | Ori Efrati, MD | Sheba Medical Center |
ClinicalTrials.gov Identifier: | NCT00552825 |
Other Study ID Numbers: |
SHEBA-05-3889-OE-CTIL Observational |
First Posted: | November 2, 2007 Key Record Dates |
Last Update Posted: | November 2, 2007 |
Last Verified: | November 2007 |
acute lymphoblastic leukemia long-term lung function |
Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Leukemia, Myeloid, Acute Leukemia, Myeloid Hodgkin Disease Neoplasms by Histologic Type |
Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma |